Quintrio
Home

INDUSTRIAL INSTRUMENTS FOR MEASUREMENT, DISPLAY, AND CONTROL

Mesa Laboratories Inc

MLAB

Mesa Laboratories Inc manufactures life sciences tools and critical quality control solutions. It operates in four divisions: i) Sterilization and Disinfection Control, which manufactures and sells biological, chemical, and cleaning indicators used to assess the effectiveness of sterilization, decontamination, disinfection, and cleaning processes. ii) Clinical Genomics division develops, manufactures, and sells sensitive, low-cost, high-throughput genetic analysis tools and related consumables. iii) The Biopharmaceutical Development division develops, manufactures, and sells automated systems for protein analysis (immunoassays) and peptide synthesis solutions. iv) The Calibration Solutions division develops, manufactures, sells, and services quality control products.

Last trade $134.30
Day change +$0.21 (+0.16%)
Day range $131.86 – $136.16
Volume 55,286
Market cap $754M

Open XNAS

Fundamentals

Key company ratios and reported financial statements.

Source: Massive.com

Key ratios

Valuation

Market capitalization
$753.66M
Price / earnings
113.08×
Price / book
3.87×
Price / sales
3×
EV / sales
3.43×
EV / EBITDA
17.68×

Profitability

Earnings per share
$1.19
Return on assets
1.63%
Return on equity
3.43%
Dividend yield
0.47%

Liquidity and leverage

Debt / equity
0.68×
Current ratio
1.9×
Quick ratio
1.39×
Cash ratio
0.43×

Cash flow

Price / cash flow
14.62×
Price / free cash flow
15.24×
Free cash flow
$49.45M

Ratios use trailing-twelve-month financials and market data as of Nov 16, 2026.

Financial statements

Income and cash flow amounts are for the period; balance sheets are point-in-time snapshots. Amounts are shown in USD. Latest 8 quarterly or 5 annual periods are displayed when available.

Income statement for MLAB, quarterly periods
Line itemQ2 FY2027 Sep 30, 2026Q1 FY2027 Jun 30, 2026Q4 FY2026 Mar 31, 2026Q3 FY2026 Dec 31, 2025Q2 FY2026 Sep 30, 2025Q1 FY2026 Jun 30, 2025Q4 FY2025 Mar 31, 2025Q3 FY2025 Dec 31, 2024
Revenue$62.34M$60.14M$63.72M$65.13M$60.74M$59.54M$62.14M$62.84M
Cost of revenue$22.46M$21.13M$21.52M$23.33M$23.41M$22.6M$23.72M$23.09M
Gross profit$39.88M$39.01M$42.21M$41.8M$37.33M$36.94M$38.41M$39.75M
Selling, general and administrative$26.44M$27.26M$34.21M$28.79M$27.56M$28.89M$31.85M$28.92M
Research and development$5.05M$4.73M$5.25M$5.03M$5.05M$4.98M$5.1M$5.05M
Total operating expenses$31.49M$31.98M$39.46M$33.82M$32.61M$33.88M$36.94M$33.98M
Operating income$8.39M$7.03M$2.75M$7.98M$4.72M$3.06M$1.47M$5.78M
Interest expense-$2.14M-$2.36M-$2.6M-$3.04M-$2.86M-$2.2M-$2.52M-$2.84M
Income before taxes$6.03M$4.35M-$1.59M$4.6M$2M$7.01M$461K-$2.22M
Income taxes$1.69M$1.52M$2.54M$966K-$477K$2.27M$7.58M-$541K
Net income$4.34M$2.83M-$4.14M$3.63M$2.48M$4.74M-$7.11M-$1.68M
Net income attributable to common shareholders$4.34M$2.83M-$4.14M$3.63M$2.48M$4.74M-$7.11M-$1.68M
EBITDA$13.95M$12.68M$8.5M$13.69M$10.57M$9.02M$8.97M$11.28M
Basic earnings per share$0.77$0.50-$0.75$0.66$0.45$0.87-$1.31-$0.31
Diluted earnings per share$0.75$0.49-$0.74$0.65$0.45$0.85-$1.33-$0.31

Recent news

Company coverage with links to the original publishers.

Publication times in UTC
The Motley Fool

Why Mesa Laboratories Stock Is Getting Hit With a Huge Sell-Off Today

Mesa Laboratories stock plummeted 19.5% on May 27, 2026, after reporting Q4 fiscal 2026 results. While the company beat expectations on adjusted operating income per share ($3.30 vs. $1.54 estimate), sales of $63.72 million fell short of Wall Street expectations by approximately $1.48 million. CEO Siddhartha Kadia is conducting an internal review and will provide full-year guidance with the Q2 report.

GlobeNewswire Inc.

MESA LABS DECLARES QUARTERLY DIVIDEND

Mesa Laboratories announced a quarterly dividend of $0.16 per share, payable on September 15, 2025, to shareholders of record as of August 29, 2025.

GlobeNewswire Inc.

MESA LABS DECLARES QUARTERLY DIVIDEND

Mesa Laboratories, Inc. (MLAB) announced a regular quarterly dividend of $0.16 per share, payable on June 16, 2025. The company is a global leader in life science tools and quality control solutions for the pharmaceutical, healthcare, and medical device industries.

GlobeNewswire Inc.

Mesa Labs Announces Second Quarter Results

Mesa Laboratories, Inc. reported its second quarter fiscal year 2025 results, with revenues increasing 8.8% year-over-year. The company's Biopharmaceutical Development and Calibration Solutions divisions saw strong growth, while the Clinical Genomics division faced headwinds in China and North America.

GlobeNewswire Inc.

MESA LABS DECLARES QUARTERLY DIVIDEND

Mesa Laboratories, Inc. (NASDAQ:MLAB) announced that its Board of Directors has declared a regular quarterly dividend of $0.16 per share of common stock, payable on December 16, 2024, to shareholders of record at the close of business on November 29, 2024.

Dividends

Declared distributions and recorded event dates. Forecasts are not shown.

Updated daily
Declared upcoming dividend $0.16 per share
Declared
Oct 8, 2026
Ex-dividend
Nov 30, 2026
Pay date
Dec 15, 2026
Ex-dividendAmount / sharePay dateType
Aug 31, 2026$0.16Sep 15, 2026recurring
May 29, 2026$0.16Jun 15, 2026recurring
Feb 27, 2026$0.16Mar 16, 2026recurring
Nov 28, 2025$0.16Dec 15, 2025recurring
Aug 29, 2025$0.16Sep 15, 2025recurring

Stock splits

Historical share-structure events and their execution dates.

Updated daily

No stock split records found.